Review
References
|
Akwafuo S, Guo S, Nikler A (2018). Epidemiological Modelling of vaccination and reduced funeral rates interventions on the production number, of Ebola virus disease in West Africa. Journal of Infectious Diseases Medicine and Microbiology 2(3):7-11. |
|
|
ASM (2014). Ebola, Marbug viruses edit genetic material during infection. American Society for Microbiology, Public Release 4 Nov. |
|
|
Bard EM (2015). Ebola virus.Clear and present danger. Journal of Clinical Microbiology 53(1):4-8. |
|
|
Bell A, Lewandowki K, Nuers R, Wooldridge D, Aarons E, Simpson A, Vipond R, Jacobs N, Gharbia S, Zambon M (2015). Genome sequence analysis of Ebola virus in clinical samples from the British healthcare worker, August 2014 to 2015. European Surveillance 20(20):1-5. |
|
|
Bixler SL, Duplantier AJ, Bavari S (2017).Discovering drugs for the treatment of Ebola virus. Current Treatment Opinions in Infectious Diseases 9(3):299-317. |
|
|
Broadhurst MJ, Brooks TJG, Pollock NR (2016). Diagnosis of ebola virus disease.Past, present and future. Clinical Microbiology Review 29(4):773-973. |
|
|
Butler D (2018). WHO says Africa's latest Ebola outbreak is not an international emergency. Nature 513:13-14. |
|
|
Cox DBT, Platt RJ, Zhang F (2015).Therapeutic genome editing: prospects and challenges. Nature Medicine 21(2):121-131. |
|
|
Cross RW, Mire CE, FEldmann H, Geisbert TW (2018). Post-exposure treatments for Ebola and Marburg virus infection. Nature Review and Drug Discovery 17(6):413-434. |
|
|
De la Vega MA, Steon D, Kobinger GP (2015). Ebola virus evolution: past and present. Plos Pathology 11(11):1-10. |
|
|
Dellicomr S, Baele G, Dudas G, Faria NR, Pybus OG, Suchard MA, Ranbaut A, Lamey P (2018). Phylodynamic assessment of intervention strategies for the West African ebola virus outbreak. Nature Communication 9(1):1-9. |
|
|
Dunning J, Sahr F, Rojek A, Gannon F, Carson G, Idriss B, Massaquol T, Gandi R, Joseph S, Osman HK, Brooks TJG, Simpson AJH, Goodfellow I, Thorne L, Arias A, Merson L, Castle L, Howell-Jones R, Parinaz-Solis R, Hope-Gill B, Ferri M, Grove J, Kowalski M, Stepniewska K, Lang T, Whitehead J, Olliaro P, Samai M, Horby PW (2016). Experimental treatment of Ebola virus disease with TKM-130803: a single arm phase 2 clinical trial. Plos Medicine 13(4):e1001997. |
|
|
Feldmann H, Geisbert TW (2011). Ebola hemorrhagic fever. Seminar 377:849-862. |
|
|
Formenty P (2018). Ebola virus disease. In: Emerging Infectious Disease, pp. 121-134. |
|
|
Geoghegan JL, Holmes ET (2018). The phytogenomic of evolving virus vitulence. Nature Review Genetics 19:756-769. |
|
|
Goldstein T, Anthony SJ, Gbakima A, Bird BH, Bangura J, Tremeau-Bravad A, Beleganhali MN, Wells HL, Dhanota JK, Liang E, Grodus M, Jangra RK, De Jesus VA, Lasso G, Smith BR, Janibai A, Kamaia BO, Kamara S, Bangura W, Monagin C, Shapira S, Johnson CK, Haque A, Hober D, Blondiaux J (2015). Addressing therapeutic options for Ebola virus infection in current and future outbreaks. Antimicrobial Agents Chemotherapy 59(10). |
|
|
Hampton T (2014).largest ever outbreak of Ebola virus disease thrusts experimental therapies, vaccines into spot light. Journal of American Medical Association 312(10):987-989. |
|
|
Haque A, Hober D, Blondlaux J (2015). Addressing therapeutic options for Ebola virus infection current and future outbreak. Antimicrobial Agents Chemotherapy 59(10):5892-5902. |
|
|
Hayden FG, Friede M, Bausch DG (2017). Experimental therapies for Ebola virus disease: what have we learnt? Journal of Infectious Diseases 215(2):167-170. |
|
|
Janus BM, Van Dyk N, Zhao X, Howel KA, Soto C, Aman MJ, Lit, Fuerst TR, Ofek G (2018). Structural basis for broad neutralization of ebolaviruses by an antibody targeting the glycoprotein fusion gap. Nature Communication 9(1):1-12. |
|
|
Jun SR, Leuze MR, Nookaew I, Uberbacher EC, Land N, Zhang Q, Wanchai V, Chai J, Nielsen N, Trolle T, Lund O, Buzard GS, Pedersa, TD, Wassenaar TM, Ussery DW (2015).Ebola virus comparative genomics. EEMS Microbiology Review 39:764-778. |
|
|
Kadanali A, Karazog G (2015). An overview of ebola virus disease. NCL 2(1):81-86. |
|
|
Kondratowicz AS, Maury WJ (2012). Ebolavirus: a brief review of novel therapeutic targets. Future Microbiology 7(1):1-4. |
|
|
Lamplard KB, Valiguette L (2014). Ebola virus disease. Canadian Journal of infectious Diseases Medicine and Microbiology 25(3):128-129. |
|
|
Lanini S, Portela G, Vairo F, Kobinger GP, Pensenti A. Langer M, Kabia S, Bogiati G, Amone J, Fang LQ, Tang T, Jiang JF, Yao HN, Kargbo D, Li XL, Jian S, BG, Kargbo B, Tong TG, Wang YW, Liu K, Kamara A, Dafae F, Kanu A, Jiang RR, Sun T Sun RX, Chen WJ, Ma MJ, Dean NE, Thomas H, LonginiJr IM, Hallirap ME, Cao WC (2016). Transmission dynamics of Ebola virus disease and intervention effectiveness on Sierra Leone. PNAS 113(16):448-4493. |
|
|
Liu SQ, EngCl, Tuan CM, Raynev S, Zhang B (2015).Identifying the pattern of molecular evolution for Zaire Ebola virus in the 2014 outbreak in West Africa. Infection, Genetics and Evolution 32:51-59. |
|
|
Maxmen A (2018a). Experimental ebola drugs face tough test in war zone. Nature 561(7721):14-15. |
|
|
Maxmen A (2018b) Latest outbreak. Nature 560(7718):289-290. |
|
|
Maxmen A (2018c). Ebola detectives race to identify hidden sources of infection as outbreak spreads. Nature 564(7735):174-175. |
|
|
Michalek P, Krejcova L, Adam V, Kizek R (2015). Epidemiology and pathogenesis of Ebola viruses. Journal of Metal Nanotechnology 1:48-52. |
|
|
Rid A, Emmanuel JE (2014). Clinical considerations of experimental intervention in the Ebola outbreak. Lancet 384(9957):1896-1899. |
|
|
Saganuwan SA, Onyeyili PA (2012). Haematonic and plasma expander effects of aqueous extract of Abrusprecatorius leaf in Musmusculus. Comparative Clinical Pathology 21(6):1249-1255. |
|
|
Saganuwan SA, Onyeyili PA, Etuk EU (2014). Immunomodulatory potential of aqueous leaf extract of Abrusprecatorius in mice. Journal of Haematology Research 1(2):54-62. |
|
|
Saganuwan SA (2017). Functional chemical groups that may likely become a source for the synthesis of novel central nervous system (cns) acting drugs. Central Nervous System Agents in Medicinal Chemistry 17 (3):178-186. |
|
|
Sanchez A, Kiley NP, Holloway BP, McCormick JB, Aupevin DD (1989). The nucleoprotein gene of ebola virus: Cloning, sequencing, and in vitro expression 170(1):81-91. |
|
|
Sugita T, Matsunami H, Kawaoka T Noda T, Wolf M (2018). Cryo-EM structure of the ebola virus nucleoprotein- RNA, complex at 3-6 A resolution. Nature 653(7729):137-140. |
|
|
Sullivan N, Tang, ZT, Nabel GJ (2003). Ebola virus pathogenesis: Implications for vaccines and therapies. Journal of Virology 77(3):9733-9737. |
|
|
Swetha RG, Ramaiah S, Anbarabu A, Sekar K (2016). Ebola virus database: gene and protein information resource for Ebolavirus. Advance Bioinformatics, pp. 1-4. |
|
|
Urbanowicz RA, McClere CP, Sakuntabhai A, Shall AA, Kobinger G, Muller MA, Holmes EC, Rey FA, Simon-loriere E, Ball JK (2016). Human adaptation of Ebola virus during the West African outbreak. Cell 167(4):1079-1087. |
|
|
Van Puyvelde S, Argimon S (2018). Sequencing in the time of ebola. Nature Review Microbiology 17(1):5-5. |
|
|
WHO (2014).Laboratory diagnosis of Ebola virus disease. Interim Guideline World Health Organization, 19 Sept. 1-4. |
|
|
WHO (2017).Emergencies preparedness, response.World Health Organization. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
